Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Aug 7, 2025 | RGA Investment Advisors | - | - | AWE LN, CRSP, FEVR LN, MTN, PTON, PYPL, ROKU, WDAY | asymmetry, balanceSheet, conviction, innovation, technology | The portfolio leans into high-conviction positions amid volatility, particularly in innovative growth businesses. Market dislocations from tariffs and macro shocks are viewed as opportunities rather than risks. Long-term value creation is driven by asymmetric setups and balance sheet strength. | MTN AWE PYPL FEVR ROKU WDAY PTON CRSP |
View |
| 2024 Q2 | Jun 30, 2024 | ACATIS Investment | - | 6.7% | 0268 HK, 2020 HK, 2330 TT, AMKR, APE AU, BLUE, BNTX, CRBU, CRSP, FMG AU, GNK GR, NBIX, PLTR, SWKS, ZEAL DC | Artificial Intelligence, EU Debt Crisis, fiscal policy, Rate Cuts, Sovereign Bonds | The July 2024 investment report highlights mounting structural pressures in Europe, including rising sovereign debt risks in France, demographic headwinds, and increased defense spending as the peace dividend fades. With France's debt-to-GDP above 110% and deficits exceeding EU thresholds, concerns about another EU debt crisis are resurfacing, potentially impacting bond spreads and refinancing conditions. Against this backdrop of geopolitical fragmentation and fiscal strain, ACATIS positions portfolios toward resilient global equities, AI beneficiaries, and selectively attractive fixed income opportunities benefiting from potential rate cuts. | CRBU CRSP GNK GR 2020 HK FMG AU BNTX SWKS PLTR |
View |
| 2025 Q3 | Oct 8, 2025 | Orbis Global Equity | - | - | ALNY, CRSP, GMAB, INSM | Biotechnology, Gene Therapy, healthcare, innovation, Value Investing | Orbis highlights the structural shift toward domestic consumption in Asia as export-led growth models unwind. The fund identifies undervalued consumer-oriented franchises benefiting from rising incomes and local demand. Consumption-driven growth remains a long-duration opportunity as economic rebalancing unfolds. | CRSP INSM GMAB DC ALNY |
View |
| 2025 Q3 | Oct 16, 2025 | Contrarius Global Equity Fund | 30.9% | 45.0% | BEAM, CRSP, NTLA, TSLA, WBD | Artificial Intelligence, Biotechnology, CRISPR, Gene Editing, Robotics | The fund highlights the transformative impact of artificial intelligence across industries, suggesting that AI adoption is still early and could surpass the internet in economic influence. It also emphasizes opportunities in the biotechnology sector, particularly gene editing technologies such as CRISPR-Cas9 and base editing, which could redefine healthcare through functional cures. Contrarius views both AI and biotech as undervalued long-term growth themes with substantial innovation-driven upside. | BEAM NTLA CRSP |
View |
| 2025 Q4 | Jan 14, 2026 | ARK Investment Management LLC | 0.0% | 0.0% | ACHR, AMD, AVAV, COIN, CRSP, DE, GH, GOOG, HOOD, KTOS, PLTR, RBLX, RKLB, ROKU, SHOP, TEM, TER, TRMB, TSLA, TWST | AI, crypto, defense, Genomics, innovation, productivity, Robotics, technology | ARK believes convergences among major platforms like AI, robotics, energy storage, public blockchain technology, and multiomics sequencing should accelerate non-farm productivity growth to 4–6% on a year-over-year basis. AI-related spending boom on data centers and power plants began in late 2022. Strong demand for AI-related chip testing and semiconductor testing across compute, networking, and memory. Robotics is identified as one of the major transformative innovation platforms that should converge with AI and other technologies to drive productivity gains. The ARK Autonomous Technology and Robotics ETF focuses on companies developing autonomous mobility, humanoid robots, and intelligent devices. Energy storage is highlighted as one of the key transformative innovation platforms that will converge with AI, robotics, blockchain, and multiomics sequencing to accelerate productivity growth and economic transformation in the coming years. ARK sees favorable policy shifts around crypto as supportive headwinds shifting into structural tailwinds for innovation. Coinbase faced challenges from weakness in crypto market trading activity, with quarterly spot trading volumes declining 9% quarter-over-quarter. The firm maintains exposure through Bitcoin ETFs and crypto-related companies. Multiomics sequencing is identified as one of the major transformative platforms. The genomics space benefited from increasingly positive sentiment following Abbott's acquisition of Exact Sciences. Companies like Guardant Health and Natera showed strong performance with significant revenue growth and clinical trial successes. Defense spending represents a significant opportunity with the U.S. Army announcing plans to purchase at least one million drones in the next 2–3 years. Companies like Kratos Defense, AeroVironment, and Rocket Lab are positioned in this space, though innovation-based defense stocks experienced broad sell-offs during the quarter. | View | |
| 2024 Q2 | Jun 30, 2024 | Loomis Sayles Global Growth Fund | 3.5% | 10.4% | ADYEY, CRSP, GOOG, RNA, SHOP, TCEHY | - | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Fund Letters | Dr. Hendrik Leber | CRISPR Therapeutics AG | Health Care | Pharmaceuticals | Bull | NASDAQ | Commercialization, Editing, Genome, Hematology, Partnership, Profit | View Pitch |
| Jan 8, 2026 | Fund Letters | Jason Gilbert | CRISPR Therapeutics AG | Health Care | Biotechnology | Bull | NASDAQ | Asymmetric, Biotech, cash-rich, Gene Editing, pipeline | View Pitch |
| Nov 29, 2025 | Fund Letters | Ben Preston | CRISPR Therapeutics AG | Health Care | Biotechnology | Bull | NASDAQ | Casgevy, Cash runway, Gene Editing, Launch curve, Reimbursement, Scalability, Vertex partnership | View Pitch |
| Nov 29, 2025 | Fund Letters | Simon Raubenheimer | CRISPR Therapeutics AG | Health Care | Biotechnology | Bull | NASDAQ | Commercialization, Gene Editing, One-and-done, Optionality, pipeline, profitability | View Pitch |
| Aug 8, 2025 | Seeking Alpha | Marc Gerstein | CRISPR Therapeutics | Health Care | Biotechnology | Bull | NASDAQ | — | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||